S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case (2014/3/24)|
|Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe (2014/3/14)|
|Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C (2014/4/7)|
|Idenix Announces Nucleotide Prodrug (IDX21437) and NS5A Inhibitor (Samatasvir) Poster Presentations at 49th Annual Meeting of the European Association for the Study of the Liver (2014/3/24)|
|Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2013 Financial Results (2014/2/27)|
|Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir (2014/1/13)|
|Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Patent Interference (2014/1/29)|
|Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2013 Financial Results and Provides HCV Pipeline Update (2013/10/30)|
|Idenix Pharmaceuticals to Present at Two Upcoming Healthcare Conferences ()|
|Idenix Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference (2014/1/7)|
Click above to view more mutual fund data and stats for idix - Idenix Pharmaceuticals, Inc..